Get the Stockscreener App
133.58
0.55%
0.73
After Hours:
134.00
0.42
+0.31%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $133.58, with a volume of 14.24M.
It is up +0.55% in the last 24 hours and up +2.36% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$132.85
Open:
$132.88
24h Volume:
14.24M
Relative Volume:
2.02
Market Cap:
$232.41B
Revenue:
$42.34B
Net Income/Loss:
$13.50B
P/E Ratio:
17.33
EPS:
7.71
Net Cash Flow:
$6.66B
1W Performance:
+1.74%
1M Performance:
+2.36%
6M Performance:
+12.47%
1Y Performance:
+31.30%
1-Day Range:
$131.74
$134.12
1-Week Range:
$131.35
$134.12
52-Week Range:
$99.71
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
133.58 | 228.44B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
105.26 | 154.60B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.64 | 143.93B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
82.98 | 103.43B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.22 | 43.99B | 5.54B | 4.18B | 623.10M | 7.00 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Tendyne TMVR secures FDA clearance - BioWorld MedTech
Cardiac Marker Analyzer Market Is Booming WorldwideAbbott, Roche Diagnostics - openPR.com
Abbott Labs (ABT) Stock Ticks Lower: Gauging the Pulse and Future Price Points - Daily Chhattisgarh News
Abbott Benefits From Libre & Biosimilars Amid FX, Cost Headwinds - TradingView
Cancer Cell Market Projected to Witness Massive GrowthAbbott Laboratories, Novartis - openPR.com
Abbott (ABT) Rises Higher Than Market: Key Facts - Yahoo Finance
Syphilis Market Growth Projections 2023-2032: DelveInsight - openPR.com
MotoAmerica Adopts Ground-Breaking Global Standard for Concussion Safety with Abbott's i-STAT TBI Blood Test - Sports Illustrated
Abbott reports positive dual-chamber pacemaker results - MassDevice
Drug Device Combination Products Market Analysis Report 2025-2030: Discover the Latest Advances and Opportunities - GlobeNewswire Inc.
An Abbott competitor drops out — plus, a special circumstance for Nvidia earnings - CNBC
Abbott Laboratories (NYSE:ABT) Gains FDA Nod For Tendyne Mitral Valve System - simplywall.st
Abbott (ABT) Gains Marginal Benefit from Boston Scientific's Str - GuruFocus
Cancer Diagnostics Market Is Booming WorldwideRoche, Abbott Laboratories - openPR.com
Abbott Stock Gains Following FDA Approval of the Tendyne System - Yahoo
The Zacks Analyst Blog Highlights Coca-Cola, Abbott Laboratories and AT&T - Yahoo Finance
Cardiac Implants Market Is Booming Worldwide | Abbott - openPR.com
Abbott Gains FDA Approval for Tendyne™, Strengthening Its Minimally Invasive Heart Portfolio - Yahoo Finance
Abbott Stakes Claim in TMVR Market with New FDA Approval - Medical Device and Diagnostic industry
Top Stock Reports for Coca-Cola, Abbott & AT&T - Yahoo Finance
Abbott Laboratories’ SWOT analysis: diversified portfolio bolsters stock amid challenges - Investing.com
FDA approves self-expanding Tendyne TMVR device from Abbott - Cardiovascular Business
Abbott wins approval for open-heart surgery-free valve replacement - Crain's Chicago Business
Biochips Market Poised Boom | Abbott Laboratories, Agilent Technologies, Inc., PerkinElmer, Inc - openPR.com
Abbott Labs (ABT) Receives FDA Approval for Tendyne Heart Valve System - GuruFocus
FDA approves Abbott mitral valve replacement device that doesn't require open-heart surgery - MassDevice
Abbott gets FDA nod for Tendyne valve for mitral valve disease - Seeking Alpha
Abbott Says Tendyne Transcatheter Mitral Valve Replacement System Receives FDA Approval - marketscreener.com
Abbott’s Tendyne valve gets FDA nod for mitral replacement By Investing.com - Investing.com Canada
Abbott (ABT) Receives FDA Approval for Tendyne Heart Valve System | ABT Stock News - GuruFocus
Abbott’s Tendyne valve gets FDA nod for mitral replacement - Investing.com
Oman Dietary Supplements Market Forecast Report to 2030, with Profiles of Nature's Way, Amway, Pfizer Gulf, Abbott Laboratories, Herbalife Nutrition, Nestle & Oman Pharmaceutical Products - GlobeNewswire
A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT) - Yahoo Finance
Abbott Laboratories: Why Wall Street's Skepticism Misses The Real Story - Seeking Alpha
If You Invested $10K In Abbott Laboratories Stock 10 Years Ago, How Much Would You Have Now? - Yahoo Finance
Abbott Laboratories (ABT) Benefitted From Better Execution - MSN
STHS unveils groundbreaking lab upgrade from Abbott at St. Tammany Parish Hospital - an17.com
Abbott Laboratories (NYSE:ABT) Collaborates On Advanced Diabetes Management With Glucose-Ketone Sensor Integration - simplywall.st
Abbott Laboratories (ABT) was up 16% in Q1 - Insider Monkey
Was Jim Cramer Right About Abbott Laboratories (ABT)? - MSN
Blood Glucose Monitoring (BGM) Devices Market Report 2025: Hospitals Lead in Blood Glucose Monitoring Device Usage, Home Care Grows Fastest - GlobeNewswire Inc.
From Acquisition to Advantage: Abbott's Growth in Heart Care - Yahoo Finance
Abbott vs. Medtronic: Which Dividend-Paying MedTech Stock is Better? - Yahoo Finance
Researchers question reliability of Abbott’s rapid malaria tests - Science | AAAS
Senseonics Holdings, Inc. Secures $57.5 Million in Public Offering and $20.3 Million from Private Placement with Abbott Laboratories - Nasdaq
Senseonics Secures Massive $77.8M Funding Boost as Abbott Backs Next-Gen Diabetes Monitor Launch - Stock Titan
The Growth Of Medical Devices Needs To Continue In Order To Invest In Abbott (NYSE:ABT) - Seeking Alpha
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Do Abbott Laboratories' (NYSE:ABT) Earnings Warrant Your Attention? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Alcon (ALC) - The Globe and Mail
Solid Results Boosted Abbott Laboratories’ (ABT) Performance in Q1 - Insider Monkey
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):